CYTK - Cytokinetics, Incorporated

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
8.26
-0.10 (-1.14%)
As of 9:54AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close8.35
Open8.30
Bid8.25 x 1100
Ask8.25 x 800
Day's Range8.25 - 8.35
52 Week Range6.75 - 15.95
Volume25,437
Avg. Volume330,862
Market Cap447.4M
Beta1.79
PE Ratio (TTM)N/A
EPS (TTM)-2.52
Earnings DateJul 31, 2018 - Aug 6, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.71
Trade prices are not sourced from all markets
  • GlobeNewswire4 days ago

    Cytokinetics Announces Data From Phase 2 Clinical Study of Reldesemtiv in Patients With Spinal Muscular Atrophy Presented at the 2018 Annual Cure SMA Conference

    Cytokinetics, Incorporated (CYTK) today announced data from the Phase 2 clinical study of reldesemtiv in patients with spinal muscular atrophy (SMA) were presented in an oral presentation by John W. Day, M.D., Ph.D., Professor of Neurology and Pediatrics (Genetics), Stanford University, at the 2018 Annual Cure SMA Conference in Dallas. In collaboration with Astellas, Cytokinetics is developing reldesemtiv as a potential treatment for people with SMA and certain other debilitating diseases and conditions associated with skeletal muscle weakness and/or fatigue. The study, which examined two dose levels of reldesemtiv, 150 mg or 450 mg twice daily, demonstrated dose-dependent increases in 6MWD in ambulatory patients as measured at both post-baseline time points, week four and week eight.

  • GlobeNewswire7 days ago

    Cytokinetics to Present at the JMP Securities Life Sciences Conference

    Cytokinetics, Inc. (CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the JMP Securities Life Sciences Conference on Wednesday, June 20, 2018 at 11:00 AM EDT at the St. Regis Hotel in New York. The webcast replay of the presentation will be archived on the Presentations page within the Investors & Media section of Cytokinetics' website for 90 days following the conclusion of the event. Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining.

  • SmarterAnalyst9 days ago

    3 Biotechs with Upcoming Data to Watch

    Cytokinetics (NASDASQ:CYTK) looks to turn around their fortunes following last year’s unsuccessful readout of Tirasemtiv in ALS. The company’s follow on asset Reldesemtiv, is built on the same mechanism but looks to resolve the dropout issue. Further, the drug seems to be more potent than its predecessor, which may help amplify the signal we saw in respiratory function.

  • GlobeNewswire12 days ago

    Cytokinetics Announces Data From Phase 2 Clinical Study of Reldesemtiv in Patients With Spinal Muscular Atrophy to be Presented at the 2018 Annual Cure SMA Conference on June 16, 2018

    Cytokinetics, Incorporated (CYTK) today announced that data from the Phase 2 clinical study of reldesemtiv in patients with spinal muscular atrophy (SMA) will be presented in an oral presentation at the 2018 Annual Cure SMA Conference in Dallas on June 16, 2018. Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining.

  • June Best Growth Stocks
    Simply Wall St.15 days ago

    June Best Growth Stocks

    Looking to add potential meaningful upside to your portfolio, but unsure where to start? Stocks such as Globant and Cytokinetics are considered to be high growth in terms of howRead More...

  • Are Options Traders Betting on a Big Move in Cytokinetics (CYTK) Stock?
    Zacks15 days ago

    Are Options Traders Betting on a Big Move in Cytokinetics (CYTK) Stock?

    Investors in Cytokinetics (CYTK) need to pay close attention to the stock based on moves in the options market lately.

  • GlobeNewswirelast month

    Cytokinetics and Cure SMA Renew and Expand Partnership to Advance Education and Awareness of SMA

    Cure SMA and Cytokinetics today announced an expanded partnership to increase education, awareness and fundraising for spinal muscular atrophy (SMA).  As a National Platinum Partner for 2018, Cytokinetics will lend support to several of Cure SMA’s initiatives at both the local and national level to advance understanding of, and research toward potential treatments for SMA, a genetic disease that robs people of physical strength and takes away their ability to walk, eat or breathe. Cytokinetics will sponsor the 2018 Annual SMA Conference as a Visionary Sponsor, increasing support for this unique event which brings together families affected by SMA, along with researchers and clinicians, to network, learn, and collaborate.

  • GlobeNewswirelast month

    Cytokinetics to Hold Annual Meeting of Stockholders

    Cytokinetics, Incorporated (CYTK) today announced that its Annual Meeting of Stockholders will be held on Wednesday, May 16, 2018 at 10:30 AM Pacific Time at the Embassy Suites Hotel, located at 250 Gateway Boulevard in South San Francisco, CA. Robert I. Blum, President and Chief Executive Officer, is scheduled to present an overview of Cytokinetics’ performance. Interested parties may access the live webcast of this presentation by visiting the Investors & Media section of Cytokinetics’ website at www.cytokinetics.com.

  • GlobeNewswire2 months ago

    Cytokinetics and the ALS Association Renew Partnership to Advance the Fight Against ALS

    Cytokinetics, Incorporated (CYTK) and The ALS Association today announced the continuation of their partnership in the fight against ALS. “We have enjoyed our longstanding, successful collaboration with The ALS Association and look forward to continuing our partnership to support the ALS community,” said Robert I. Blum, Cytokinetics’ President and Chief Executive Officer.

  • ACCESSWIRE2 months ago

    Blog Exposure - Zealand’s End-of-Phase-2 Meeting with FDA Confirmed the Path Forward for Phase-3 Program of Glepaglutide for Short Bowel Syndrome

    LONDON, UK / ACCESSWIRE / April 30, 2018 / Active-Investors.com has just released a free research report on Zealand Pharma A/S (NASDAQ: ZEAL) ("Zealand"). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ZEAL as the Company's latest news hit the wire. On April 26, 2018, the Company announced that it has successfully concluded the End-of-Phase-2 meeting with the US Food and Drug Administration (FDA) regarding the Phase-3 program for Zealand's long-acting GLP-2 analog, glepaglutide, in short bowel syndrome (SBS) patients.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of CYTK earnings conference call or presentation 26-Apr-18 8:30pm GMT

    Q1 2018 Cytokinetics Inc Earnings Call

  • Associated Press2 months ago

    Cytokinetics: 1Q Earnings Snapshot

    The South San Francisco, California-based company said it had a loss of 56 cents per share. The biopharmaceutical company posted revenue of $5.3 million in the period. Cytokinetics shares have declined ...

  • GlobeNewswire2 months ago

    Cytokinetics, Inc. Reports First Quarter 2018 Financial Results

    Completed Enrollment in Phase 2 Study of Reldesemtiv in Patients with SMA; Data Expected in Q2 2018. Preparing to Initiate Second Phase 3 Clinical Trial of Omecamtiv Mecarbil. SOUTH SAN FRANCISCO, Calif., ...

  • Is Cytokinetics Incorporated (NASDAQ:CYTK) Worth $7.25 Based On Intrinsic Value?
    Simply Wall St.2 months ago

    Is Cytokinetics Incorporated (NASDAQ:CYTK) Worth $7.25 Based On Intrinsic Value?

    Today I will be providing a simple run-through of the discounted cash flows (DCF) method to estimate the attractiveness of Cytokinetics Incorporated (NASDAQ:CYTK) as an investment opportunity. Anyone interested inRead More...

  • GlobeNewswire2 months ago

    Cytokinetics Announces Presentation of Data From Phase 2 Clinical Study of Reldesemtiv in Patients With Spinal Muscular Atrophy at the 2018 Annual Cure SMA Conference

    Cytokinetics, Incorporated (CYTK) today announced that data from the Phase 2 clinical study of reldesemtiv in patients with spinal muscular atrophy (SMA) will be presented by John Day, M.D., Ph.D., Professor of Neurology and Pediatrics (Genetics), Stanford University Medical Center, in an oral presentation at the 2018 Annual Cure SMA Conference in Dallas on June 16, 2018. The clinical study is designed to assess the effect of reldesemtiv, a next-generation fast skeletal muscle troponin activator (FSTA), on multiple measures of muscle function in both ambulatory and non-ambulatory patients with SMA. In collaboration with Astellas Pharma Inc. (TSE:4503) (“Astellas”), Cytokinetics is developing reldesemtiv as a potential treatment for people living with SMA and certain other debilitating diseases and conditions associated with skeletal muscle weakness and/or fatigue.

  • GlobeNewswire2 months ago

    Cytokinetics to Announce First Quarter Results on April 26, 2018

    SOUTH SAN FRANCISCO, Calif., April 12, 2018-- Cytokinetics, Incorporated today announced that it is scheduled to report first quarter results on April 26, 2018 at 4:00 PM Eastern Time. Following the announcement, ...

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of CYTK earnings conference call or presentation 15-Feb-18 9:30pm GMT

    Q4 2017 Cytokinetics Inc Earnings Call

  • Associated Press4 months ago

    Cytokinetics reports 4Q loss

    On a per-share basis, the South San Francisco, California-based company said it had a loss of 75 cents. The results did not meet Wall Street expectations. The average estimate of four analysts surveyed ...

  • ACCESSWIRE4 months ago

    Cytokinetics, Incorporated to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / February 15, 2018 / Cytokinetics, Incorporated (NASDAQ: CYTK ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 15, 2018 at 4:30 PM ...

  • What You Must Know About Cytokinetics Incorporated’s (NASDAQ:CYTK) Major Investors
    Simply Wall St.4 months ago

    What You Must Know About Cytokinetics Incorporated’s (NASDAQ:CYTK) Major Investors

    Today, I will be analyzing Cytokinetics Incorporated’s (NASDAQ:CYTK) recent ownership structure, an important but not-so-popular subject among individual investors. When it comes to ownership structure of a company, the impactRead More...

  • Benzinga4 months ago

    Cytokinetics Earnings Outlook

    Cytokinetics (NASDAQ: CYTK ) announces its next round of earnings Thursday. Here is Benzinga's everything-that-matters guide for today's Q4 earnings announcement. Earnings and Revenue Sell-side analysts ...